Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible for inclusion in the study if all of the following criteria are met:~1. Low risk prostate cancer diagnosed using one transrectal ultrasound guided biopsy (TRUS)using from 10 to 24 cores performed less than 12 months prior to enrolment, and showing the following:~   * Gleason 3 + 3 prostate adenocarcinoma as a maximum,~  * Two (2) to three (3) cores positive for cancer~  * A maximum cancer core length of 5 mm in any core.~2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease permitted)~3. Serum prostate specific antigen (PSA) of 10 ng/mL or less~4. Prostate volume equal or greater than 25 cc and less than 70 cc.~5. Male subjects aged 18 years or older.~Exclusion Criteria:~Subjects will not be eligible for the study if meeting any of the following criteria:~1. Unwillingness to accept randomisation to either of the two arms of the study~2. Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy.~3. Any surgical intervention for benign prostatic hypertrophy~4. Life expectancy less than 10 years.~5. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure.~6. Participation in another clinical study or recipient of an investigational product within 1 month of study entry.~7. Subject unable to understand the patient's information document, to give consent or complete the study tasks.~8. Subject in custody and or in residence in a nursing home or rehabilitation facility~9. Contra-indication to Magnetic resonance Imaging (MRI) (e.g., pacemaker, history of allergic reaction to gadolinium), or factors excluding accurate reading of pelvic MRI (e.g., hip prosthesis)~10. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the TOOKAD® Soluble VTP procedure.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TOOKAD® Soluble (Type: EXPERIMENTAL): TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
- Active Surveillance (Type: NO_INTERVENTION): Active surveillance is one of the management strategy in men who have low-risk prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).